(9) Income Taxes
The Company’s U.S. and foreign loss before income taxes are set forth below:
|
|
Year ended December 31, |
|
|||||||
|
|
2017 |
|
2016 |
|
2015 |
|
|||
United States |
|
$ |
(27,051,148) |
|
$ |
(18,803,227) |
|
$ |
(12,145,964) |
|
Foreign |
|
|
(4,961,156) |
|
|
(4,612,823) |
|
|
(377,843) |
|
Total |
$ |
(32,012,304) |
$ |
(23,416,050) |
$ |
(12,523,807) |
The Company had $56.8 million and $36.5 million of federal net operating loss carryforwards and $1.7 million and $1.3 million of research tax credit carryforwards as of December 31, 2017 and 2016, respectively. The U.S. federal net operating loss carryforwards and research tax credit carryforwards begin to expire in 2028 and 2027, respectively. The Company has $57.1 million and $34.4 million of state net operating loss carryforwards as of December 31, 2017 and 2016, respectively. The state net operating loss carryforwards begin to expire in 2028 and 2027, respectively. As of December 31, 2017, the Company had $0.4 million of Australia net operating loss carryforwards, which have an indefinite life.
The Tax Reform Act of 1986 (the Act) provides for limitation on the use of net operating loss and research and development tax credit carryforwards following certain ownership changes (as defined by the Act) that could limit the Company’s ability to utilize these carryforwards. The Company may have experienced various ownership changes, as defined by the Act, as a result of past financings. Accordingly, the Company’s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes; therefore, the Company may not be able to take full advantage of these carryforwards for federal income tax purposes.
The components of the net deferred income tax asset as of December 31, 2017 and 2016 are as follows:
|
|
December 31, 2017 |
|
December 31, 2016 |
|
||
Deferred tax assets: |
|
|
|
|
|
|
|
Net operating loss carry-forwards |
|
$ |
16,130,487 |
|
$ |
14,877,358 |
|
Research and development credit carry-forwards |
|
|
1,739,824 |
|
|
1,337,748 |
|
Stock-based compensation |
|
|
2,675,304 |
|
|
1,576,280 |
|
Other |
|
|
259,241 |
|
|
43,004 |
|
Gross deferred tax assets |
|
|
20,804,856 |
|
|
17,834,390 |
|
Deferred tax liabilities: |
|
|
|
|
|
|
|
Accumulated depreciation |
|
|
(29,060) |
|
|
(21,632) |
|
Gross deferred tax liabilities |
|
|
(29,060) |
|
|
(21,632) |
|
Less valuation allowance |
|
|
(20,775,796) |
|
|
(17,812,758) |
|
Net deferred tax asset |
|
$ |
— |
|
$ |
— |
|
The 2017 Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 34% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Cuts and Jobs Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI). These changes are effective beginning in 2018. The 2017 Tax Cuts and Jobs Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings.
On December 22, 2017, the SEC staff issued Staff Accounting Bulletin, or SAB, No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act. The Company has recognized the provisional tax impacts related to the revaluation of the deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017. The ultimate impact may differ from these provisional amounts due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Cuts and Jobs Act. The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018. In regard to the change in the federal tax rate as it relates to the Company’s deferred tax assets and liabilities, the Company decreased deferred tax assets by $8.7 million along with a corresponding offset against the valuation allowance for these deferred tax assets.
In assessing the realizability of deferred tax assets, the Company considers whether it is more‑likely‑than‑not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2017 and 2016, respectively, because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The valuation allowance increased by $3.0 million and $9.5 million during the years ended December 31, 2017 and 2016, respectively, due primarily to the generation of net operating loss carryforwards during those years.
The Company does not have unrecognized tax benefits as of December 31, 2017 and 2016, respectively. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:
|
|
Year ended December 31, |
|
||||
|
|
2017 |
|
2016 |
|
2015 |
|
Federal income tax benefit at statutory rate |
|
34.0 |
% |
34.0 |
% |
34.0 |
% |
State income tax, net of federal benefit |
|
6.5 |
% |
7.8 |
% |
2.9 |
% |
Foreign tax rate differential |
|
— |
% |
(0.2) |
% |
(0.1) |
% |
Nondeductible research and development expenses |
|
(5.1) |
% |
(4.7) |
% |
(1.1) |
% |
Other permanent differences |
|
(0.1) |
% |
— |
% |
(0.1) |
% |
Research and development credit benefit |
|
1.3 |
% |
3.9 |
% |
2.0 |
% |
Rate change from 2017 Tax Cuts and Jobs Act |
|
(27.3) |
% |
— |
% |
— |
% |
Change in valuation allowance |
|
(9.3) |
% |
(40.7) |
% |
(37.8) |
% |
Effective income tax rate |
|
— |
% |
0.1 |
% |
(0.2) |
% |
The Company and its subsidiaries are subject to income taxes in the U.S. federal jurisdiction, various state jurisdictions and Australia. The Company’s 2012 to 2017 tax years remain open and subject to examination.